Evommune publishes migraine presentation on MRGPRX2 antagonism

Evommune, Inc.

Evommune, Inc.

EVMN

0.00
  • Evommune published a medical research presentation outlining MRGPRX2 antagonism as a potential migraine approach targeting meningeal mast cells and trigeminal neurons.
  • The document frames mast cell–trigeminal neuron cross-talk in the meninges as a driver of migraine pain through inflammatory mediators and neuropeptides.
  • It cites evidence that MRGPRX2 is expressed in disease-relevant tissues, including meningeal mast cells and trigeminal ganglia.
  • The presentation highlights human data linking MRGPRX2 ligands such as PACAP, VIP, and substance P to migraine-like attacks in migraine patients.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Evommune Inc. published the original content used to generate this news brief on June 29, 2026, and is solely responsible for the information contained therein.

This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.